Immunosuppressive Therapy Does Not Prevent the Occurrence of Immunoglobulin E–Mediated Allergies in Children and Adolescents With Organ Transplants
- 1 September 2006
- journal article
- Published by American Academy of Pediatrics (AAP)
- Vol. 118 (3), e764-e770
- https://doi.org/10.1542/peds.2006-0370
Abstract
BACKGROUND. Allogeneic organ transplantation has become a common procedure in acute and chronic organ failure. The major limitation, rejection of the allograft by the host's immune system, can be limited by various immunosuppressive drugs that target the adaptive T-cell response. Most of these drugs are used in the treatment of allergic diseases as well, suggesting that transplant recipients under long-term immunosuppressive therapy should not develop any sensitizations or at least not show any clinical signs of allergy. Surprisingly, organ-transplanted children and adults do report symptoms of type 1 allergies, such as allergic rhinoconjunctivitis, bronchial asthma, and food allergies. Thus far, mainly case reports and series on the occurrence of allergy after orthotopic liver transplantation exist. OBJECTIVE. Our purpose with this study was to evaluate in a cross-sectional design the prevalence of immunoglobulin E-mediated sensitizations and type 1 allergies in solid organ–transplanted children and adolescents and to identify risk factors. METHODS. Seventy-eight organ-transplanted subjects (50 kidney, 9 lung, 19 liver; mean age: 14.06 ± 5.94 years; range 1.42 to 24.25 years) were studied by standardized interviews (modified International Study of Asthma and Allergies in Childhood [ISAAC] criteria), skin-prick tests, and measurement of specific and total serum immunoglobulin E. RESULTS. Nineteen patients (24.4%) were found to be sensitized to ≥1 common inhalant or food allergens, as reflected by elevated specific immunoglobulin E levels and/or positive skin-prick test results, and 8 subjects (10.3%) additionally reported a corresponding present history of atopic diseases. No severe anaphylactic reactions were reported. No statistically significant associations with gender, kind of transplanted organ, distinct immunosuppressive therapies, and age at time of transplantation or age at investigation were found (χ2 test, Fisher's exact test, and Wilcoxon rank-sum test, respectively). Multiple logistic-regression analysis did not identify any independent risk factor either. CONCLUSION. This study demonstrates that therapeutic immunosuppression does not control sensitizations and clinical manifestation of type 1 allergies in organ-transplanted children and adolescents.Keywords
This publication has 30 references indexed in Scilit:
- The development of food allergy after liver transplantationLiver Transplantation, 2005
- Guidelines of care for atopic dermatitisJournal of the American Academy of Dermatology, 2004
- Tacrolimus and food allergyTransplantation, 2003
- Type I Sensitization in Adolescents: Prevalence and Association with Atopic DermatitisPublished by Medical Journals Sweden AB ,2003
- Angioedema in pediatric liver transplant recipients under tacrolimus immunosuppressionTransplantation, 2003
- Long-term efficacy and safety of cyclosporin in severe adult atopic dermatitisBritish Journal of Dermatology, 1997
- Treatment of steroid-dependent bronchial asthma with cyclosporinEuropean Respiratory Journal, 1995
- International Study of Asthma and Allergies in Childhood (ISAAC): rationale and methodsEuropean Respiratory Journal, 1995
- Double-blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitisThe Lancet, 1991
- Serum IgE levels in healthy children quantified by a sandwich technique (PRIST*)Clinical and Experimental Allergy, 1976